Cardiovascular Systems, Inc. recently released two-year data from its LIBERTY 360° clinical study in a late-breaking presentation at the 2018 Amputation Prevention Symposium (AMP) in Chicago.
Notably, LIBERTY 360° is a prospective, observational, multi-center post-market study. The study was based on more than 1,204 patients across 51 sites in the United States, including 501 patients with claudication, 603 affected with critical limb ischemia (CLI) and 100 with the most severe form of CLI.
The study examined the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in peripheral artery disease (PAD) patients. Per the medical device manufacturer, LIBERTY 360° as an “all comers” study included all FDA-approved endovascular devices to treat PAD.
The data from this study demonstrated a continued high freedom from major amputation in all Rutherford Classifications (RC) at the end of two-year observation period. Particularly, LIBERTY 360° showed that PVI can help prevent amputation even for RC6 patients with PAD, thus demonstrating a 79.8% freedom from major amputation following PVI. This piece of solid information is validated by the company itself.
Per the company’s press release, around 18 million Americans suffer the PAD, syndrome, caused by the accumulation of plaque in peripheral arteries reducing blood flow. We believe that the company is adopting appropriate strategic moves to capture this niche market.
We also note in this regard that in February, the company announced the commercial launch of Diamondback 360 Coronary OAS Micro Crown in Japan.
Some noteworthy stocks in the broader industry are Haemonetics Corporation (HAE - Free Report) , Stryker Corporation (SYK - Free Report) and Lantheus Holdings, Inc. (LNTH - Free Report) .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Cardiovascular Systems, Inc. recently released two-year data from its LIBERTY 360° clinical study in a late-breaking presentation at the 2018 Amputation Prevention Symposium (AMP) in Chicago.
Notably, LIBERTY 360° is a prospective, observational, multi-center post-market study. The study was based on more than 1,204 patients across 51 sites in the United States, including 501 patients with claudication, 603 affected with critical limb ischemia (CLI) and 100 with the most severe form of CLI.
The study examined the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in peripheral artery disease (PAD) patients. Per the medical device manufacturer, LIBERTY 360° as an “all comers” study included all FDA-approved endovascular devices to treat PAD.
The data from this study demonstrated a continued high freedom from major amputation in all Rutherford Classifications (RC) at the end of two-year observation period. Particularly, LIBERTY 360° showed that PVI can help prevent amputation even for RC6 patients with PAD, thus demonstrating a 79.8% freedom from major amputation following PVI. This piece of solid information is validated by the company itself.
Per the company’s press release, around 18 million Americans suffer the PAD, syndrome, caused by the accumulation of plaque in peripheral arteries reducing blood flow. We believe that the company is adopting appropriate strategic moves to capture this niche market.
We also note in this regard that in February, the company announced the commercial launch of Diamondback 360 Coronary OAS Micro Crown in Japan.
Some noteworthy stocks in the broader industry are Haemonetics Corporation (HAE - Free Report) , Stryker Corporation (SYK - Free Report) and Lantheus Holdings, Inc. (LNTH - Free Report) .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on SYK - FREE
Get the latest research report on HAE - FREE
Get the latest research report on LNTH - FREE